Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Mar 28 04:00PM ET
8.60
Dollar change
-0.41
Percentage change
-4.55
%
Index- P/E- EPS (ttm)-11.75 Insider Own54.27% Shs Outstand18.70M Perf Week-21.82%
Market Cap143.94M Forward P/E- EPS next Y- Insider Trans-0.01% Shs Float8.55M Perf Month-9.57%
Income-58.77M PEG- EPS next Q- Inst Own6.17% Short Float0.67% Perf Quarter-21.15%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio2.23 Perf Half Y-51.44%
Book/sh22.48 P/B0.38 EPS next Y- ROA-38.00% Short Interest0.06M Perf Year-50.14%
Cash/sh7.07 P/C1.22 EPS next 5Y- ROE-45.37% 52W Range7.96 - 24.15 Perf YTD-10.97%
Dividend Est.- P/FCF- EPS past 5Y-6.86% ROI-51.87% 52W High-64.39% Beta0.62
Dividend TTM- Quick Ratio22.63 Sales past 5Y-20.00% Gross Margin- 52W Low8.04% ATR (14)1.18
Dividend Ex-Date- Current Ratio22.63 EPS Y/Y TTM72.12% Oper. Margin- RSI (14)39.57 Volatility17.21% 11.49%
Employees6 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom4.00 Target Price20.70
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q69.80% Payout- Rel Volume0.73 Prev Close9.01
Sales Surprise- EPS Surprise-66.26% Sales Q/Q- Earnings- Avg Volume25.53K Price8.60
SMA20-12.15% SMA50-12.05% SMA200-40.57% Trades Volume18,619 Change-4.55%
Mar-18-25 04:21PM
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company is headquartered in Palo Alto, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hagen Brett RChief Accounting OfficerMar 26 '25Sale8.979078,1351,925Mar 27 07:19 PM